Fumarate attenuated doxorubicin-induced cardiac injury through modulation of endothelial nitric oxide synthase expression and transforming growth factor-β1 signalling
Journal: Prospects in Pharmaceutical Sciences
Year: 2025

Doxorubicin (dox) is an anticancer agent with adverse effects, such as cardiac injury. Fumarate, a tricarboxylic acid cycle metabolite, has been shown to ameliorate cardiac injury. This study investigated the possible cardioprotective action of fumarate in dox-induced cardiac injury. Male Wistar rats were divided into four groups (n=8); control (distilled water 10 ml/kg, po), dox (10 mg/kg, ip), dox (10 mg/kg, ip) + fumarate (50 mg/kg, po) and dox (10 mg/kg, ip) + fumarate (100 mg/kg, po). The a